These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 33543775)
1. Migraine treatment and COVID-19 vaccines: No cause for concern. Gelfand AA; Poland G Headache; 2021 Mar; 61(3):409-411. PubMed ID: 33543775 [No Abstract] [Full Text] [Related]
2. COVID-19 vaccines for patients with haematological conditions. Sun C; Pleyer C; Wiestner A Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822 [No Abstract] [Full Text] [Related]
3. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy. Ortega Rodríguez NR; Audícana Berasategui MT; de la Hoz Caballer B; Valero Santiago A J Investig Allergol Clin Immunol; 2021 Feb; 31(1):89-91. PubMed ID: 33393485 [No Abstract] [Full Text] [Related]
4. Talk of the town in 2021: Covid-19 vaccines likely take centre stage. Höglund P Scand J Immunol; 2021 Jan; 93(1):e13014. PubMed ID: 33372339 [No Abstract] [Full Text] [Related]
6. Cancer and COVID-19 vaccines: a complex global picture. Yusuf A; Sarfati D; Booth CM; Pramesh CS; Lombe D; Aggarwal A; Bhoo-Pathy N; Tsunoda A; Vanderpuye V; Kutluk T; Sullivan A; Mukherji D; Mutebi M; van Hemelrijck M; Sullivan R; Lancet Oncol; 2021 Jun; 22(6):749-751. PubMed ID: 33930324 [No Abstract] [Full Text] [Related]
7. COVID-19 vaccines: one step towards the beginning of the end of the global impact of the pandemic. Cook TM; Farrar JJ Anaesthesia; 2021 Apr; 76(4):435-443. PubMed ID: 33316853 [No Abstract] [Full Text] [Related]
8. SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future. Winthrop KL; Whitley RJ; Aletaha D Ann Rheum Dis; 2021 Oct; 80(10):1249-1251. PubMed ID: 34518198 [No Abstract] [Full Text] [Related]
9. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine. Neurosciences (Riyadh); 2021 Apr; 26(2):222-223. PubMed ID: 33814381 [No Abstract] [Full Text] [Related]
10. A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. Makhoul AT; Drolet BC Chest; 2021 Mar; 159(3):1292-1293. PubMed ID: 33453180 [No Abstract] [Full Text] [Related]
11. Evaluating SARS-CoV-2 Vaccines After Emergency Use Authorization or Licensing of Initial Candidate Vaccines. Joffe S JAMA; 2021 Jan; 325(3):221-222. PubMed ID: 33315069 [No Abstract] [Full Text] [Related]
12. Covid-19: US Catholics split after bishops' conference recommends against Johnson and Johnson vaccine. Dyer O BMJ; 2021 Mar; 372():n666. PubMed ID: 33687968 [No Abstract] [Full Text] [Related]
13. Messenger RNA vaccines against SARS-CoV-2. Topol EJ Cell; 2021 Mar; 184(6):1401. PubMed ID: 33740443 [TBL] [Abstract][Full Text] [Related]
14. Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. Salvamani S; Tan HZ; Thang WJ; Ter HC; Wan MS; Gunasekaran B; Rhodes A Br J Biomed Sci; 2020 Oct; 77(4):168-184. PubMed ID: 32942955 [TBL] [Abstract][Full Text] [Related]